New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2013
09:25 EDTNBIX, NBIX, NBIXPiper Jaffray's biotech research team holds analyst/industry conference call
Analyst Research Team, along with Dr. Joseph Jankovic, Professor of Neurology at Baylor College of Medicine, discusses current therapies and the role of selective VMAT-2 inhibitors for tardive dyskinesia and other movement disorders, along with Neurocrine's NBI-98854, on an Analyst/Industry conference call to be held on April 5 at 10 am.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
16:11 EDTNBIXNeurocrine reports Q2 EPS (28c), consensus (29c)
Subscribe for More Information
July 27, 2015
10:40 EDTNBIXIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
July 21, 2015
10:01 EDTNBIXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:09 EDTNBIXNeurocrine resumed with an Outperform at Leerink
Leerink resumed shares of Neurocrine with an Outperform rating and $67 price target. The firm says its survey of 51 physicians who treat Tardive dyskinesia and specialist checks on endometriosis support its view that both NBI-98854 and Elagolix could achieve blockbuster status.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use